Common Contracts
5 similar Support Agreement contracts by Syros Pharmaceuticals, Inc., Tyme Technologies, Inc.
TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENTSupport Agreement • July 13th, 2022 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Syros Pharmaceuticals, Inc. a Delaware corporation (“Syros”), Tyme Technologies, Inc., a Delaware corporation (“Tyme”), and the undersigned stockholder (the “Stockholder”) of Tyme.
SYROS PHARMACEUTICALS, INC. [FORM OF] SUPPORT AGREEMENTSupport Agreement • July 5th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Tyme Technologies, Inc. a Delaware corporation (“Tyme”), Syros Pharmaceuticals, Inc., a Delaware corporation (“Syros”), and the undersigned stockholder (the “Stockholder”) of Syros.
SYROS PHARMACEUTICALS, INC. [FORM OF] SUPPORT AGREEMENTSupport Agreement • July 5th, 2022 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Tyme Technologies, Inc. a Delaware corporation (“Tyme”), Syros Pharmaceuticals, Inc., a Delaware corporation (“Syros”), and the undersigned stockholder (the “Stockholder”) of Syros.
TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENTSupport Agreement • July 5th, 2022 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Syros Pharmaceuticals, Inc. a Delaware corporation (“Syros”), Tyme Technologies, Inc., a Delaware corporation (“Tyme”), and the undersigned stockholder (the “Stockholder”) of Tyme.
TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENTSupport Agreement • July 5th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of [●], 2022, by and among Syros Pharmaceuticals, Inc. a Delaware corporation (“Syros”), Tyme Technologies, Inc., a Delaware corporation (“Tyme”), and the undersigned stockholder (the “Stockholder”) of Tyme.
